Fairvalue-Calculator Fairvalue-Calculator
EN DE

BL Pharmtech Corp (065170) Fair Value & Analysis

Consumer Defensive · KR · Market cap 46.5B KRW

Price2,110 KRW
Fair Value1,628 KRW
Upside-22.9%
Quality95/100
Evidence: Low Range 1,221 KRW – 2,035 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

BL Pharmtech Corp (065170) currently trades at 2,110 KRW, while our model-based Fair Value estimate is 1,628 KRW — implying the stock looks roughly 22.9% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

BL Pharmtech Corp. manufactures, retails, imports, and exports health functional foods in South Korea. It is also involved in biotechnology business, as well as manufacture of cosmetics. The company was formerly known as Next BT Co., Ltd. BL Pharmtech Corp. was founded in 1995 and is headquartered in Yongin-si, South Korea.

Open the full interactive analysis →

Similar stocks

Sysco Corporation (SYY) -24% US Foods Holding (USFD) -41% Performance Food Group (PFGC) -56% Jerónimo Martins, SGPS, S.A (JRONF) +9% Bunzl plc (BZLFY) -11% Bid Corporation (BPPPF) +8%

Frequently asked questions

Is BL Pharmtech Corp (065170) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 1,628 KRW versus a price of 2,110 KRW — about −23% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 065170?
Our 21-model fair value for BL Pharmtech Corp is 1,628 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 2,110 KRW.
What is the quality score of 065170?
BL Pharmtech Corp has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.